ZERO Biotech and C-Ray Therapeutics have officially signed a Strategic Collaboration Agreement in Hong Kong to bolster the regional supply chain for theranostic isotopes and accelerate the translation of novel radiopharmaceuticals across Asia.
Executives from C-Ray Therapeutics traveled from their headquarters in Chengdu to Hong Kong for the signing ceremony, marking a pivotal step forward in advancing targeted radioligand therapies for patients across the region.
The ceremony was witnessed by Dr. Cathy Lui, Principal Manager, Life & Health Sciences at InvestHK, highlighting Hong Kong’s growing stature as a regional hub for advanced healthcare and biotechnology innovation.
This strategic alliance pairs ZERO Biotech’s regional distribution infrastructure and clinical translation capabilities with C-Ray Therapeutics’ established expertise in Contract Development and Manufacturing Operations (CDMO).
The partnership focuses on two core strategic objectives:
Expanding Regional Radionuclide Networks
By combining distribution logistics and regulatory expertise, the alliance will secure and scale a reliable supply of a variety of medical isotopes to meet rising clinical demand across hospital networks in Asia.
Fast-Tracking Next-Generation Drug Pipelines
Utilizing C-Ray’s specialized CDMO capabilities, ZERO Biotech and C-Ray will streamline the process of taking novel radiopharmaceutical candidates from early-stage discovery, through process development, and into human clinical trials.
The presence of InvestHK at the signing underlines the strategic importance of cross-border partnerships in the life sciences sector. With Hong Kong actively expanding its health tech infrastructure and clinical research capabilities, partnerships bridging Mainland China’s manufacturing power with Hong Kong’s international healthcare platform are set to lead the next wave of precision oncology.